Daihan Pharmaceutical Co.Ltd (023910) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Daihan Pharmaceutical Co.Ltd (023910) has a cash flow conversion efficiency ratio of 0.032x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩9.47 Billion ≈ $6.42 Million USD) by net assets (₩293.27 Billion ≈ $198.74 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Daihan Pharmaceutical Co.Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Daihan Pharmaceutical Co.Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Daihan Pharmaceutical Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Daihan Pharmaceutical Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Daihan Pharmaceutical Co.Ltd ranked by their cash flow conversion efficiency. Explore Daihan Pharmaceutical Co.Ltd earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Maxigen Biotech Inc
TW:1783
|
0.049x |
|
Devyser Diagnostics AB
ST:DVYSR
|
0.034x |
|
Canadian Life Companies Split Corp
TO:LFE
|
0.023x |
|
Kino Indonesia Tbk PT
JK:KINO
|
0.132x |
|
RMK Energy PT Tbk
JK:RMKE
|
-0.081x |
|
Tera Autotech
TWO:6234
|
0.013x |
|
Meiloon Industrial Co Ltd
TW:2477
|
0.032x |
|
Schloss Wachenheim AG
F:SWA
|
-0.008x |
Annual Cash Flow Conversion Efficiency for Daihan Pharmaceutical Co.Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Daihan Pharmaceutical Co.Ltd from 2014 to 2024. View 023910 stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩275.99 Billion ≈ $187.04 Million |
₩35.64 Billion ≈ $24.15 Million |
0.129x | -17.59% |
| 2023-12-31 | ₩247.97 Billion ≈ $168.05 Million |
₩38.86 Billion ≈ $26.34 Million |
0.157x | +21.80% |
| 2022-12-31 | ₩225.40 Billion ≈ $152.75 Million |
₩29.00 Billion ≈ $19.65 Million |
0.129x | -35.76% |
| 2021-12-31 | ₩202.81 Billion ≈ $137.44 Million |
₩40.62 Billion ≈ $27.53 Million |
0.200x | +8.35% |
| 2020-12-31 | ₩181.92 Billion ≈ $123.29 Million |
₩33.63 Billion ≈ $22.79 Million |
0.185x | -12.58% |
| 2019-12-31 | ₩166.78 Billion ≈ $113.02 Million |
₩35.26 Billion ≈ $23.90 Million |
0.211x | -33.96% |
| 2018-12-31 | ₩140.36 Billion ≈ $95.12 Million |
₩44.94 Billion ≈ $30.46 Million |
0.320x | +81.40% |
| 2017-12-31 | ₩115.88 Billion ≈ $78.53 Million |
₩20.45 Billion ≈ $13.86 Million |
0.177x | -41.25% |
| 2016-12-31 | ₩92.94 Billion ≈ $62.99 Million |
₩27.92 Billion ≈ $18.92 Million |
0.300x | +28.43% |
| 2015-12-31 | ₩76.84 Billion ≈ $52.07 Million |
₩17.98 Billion ≈ $12.18 Million |
0.234x | +58.11% |
| 2014-12-31 | ₩64.10 Billion ≈ $43.44 Million |
₩9.48 Billion ≈ $6.43 Million |
0.148x | -- |
About Daihan Pharmaceutical Co.Ltd
Daihan Pharmaceutical Co.,Ltd. engages in the manufacture and sale of therapeutic drugs in South Korea. The company offers various drugs, such as prescription, OTC, and quasi drugs, as well as offers various infusion related solutions. Daihan Pharmaceutical Co.,Ltd. was founded in 1945 and is headquartered in Seoul, South Korea.